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Abstract
Over the past 2 years, X-ray crystal structures of the antagonist- and agonist-bound CB1 
receptor have been reported. Such structures are expected to accelerate progress in the 
understanding of CB1 and should provide an exceptional starting point for structure-
based drug discovery. This chapter examines the consistency of these X-ray structures 
with the CB1 experimental literature, including mutation, NMR and covalent labeling 
studies. These comparisons reveal discrepancies between this literature and the TMH1-
2-3 region of each CB1 crystal structure. The chapter also examines crystal packing issues 
with each X-ray structure and shows that the discrepancies with the experimental lit-
erature can be attributed to crystal packing problems that force the N-terminus deep in 
the binding pocket of the two inactive state structures and force TMH2 to bend at G2.53/
S2.54 and invade the binding pocket in the activated state structure. Revision is advisable 
before these structures are used for structure-based drug discovery.
Keywords: cannabinoid CB1 receptor, CB1 mutation, CB1 cross-linking, CB1 nuclear 
magnetic resonance, crystal packing
1. Introduction
The cannabinoid receptor type 1 (CB1) belongs to the G-protein coupled receptors (GPCRs) 
superfamily. GPCRs comprise the largest group of integral membrane proteins that mediate 
cellular responses to a wide spectrum of signaling molecules including peptides, lipids, neu-
rotransmitters, glycoproteins, as well as light, taste and odor substances. They act via coupling 
and activating intracellular effector proteins including G-proteins and arrestins leading to an 
array of intracellular signaling cascades.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
GPCRs have a common architecture of seven transmembrane helices (TMHs) joined by extra-
cellular (EC) and intracellular (IC) loops of varied lengths, in addition to an extracellularly 
extending N terminus, and an intracellular C terminus that begins with an amphipathic alpha 
helical segment (Helix 8) oriented parallel to the cell membrane. In Class A GPCRs, the bind-
ing site for the endogenous ligand is generally formed by the EC core within the TMH bundle, 
and may extend to EC loops, referred to as the orthosteric binding site. Ligands may also bind 
to distinct (allosteric) binding sites in the receptor.
Due to the various physiological functions mediated by GPCRs, they are considered major 
targets for drug discovery and design of novel therapeutics. However, understanding the 
structure-function relationship of these proteins and the design of high affinity, selective 
ligands that target these receptors requires a detailed knowledge of the three-dimensional 
structure of the receptor in general and of the ligand binding site in specific. However, struc-
tural characterization for membrane proteins in general has been a challenge due to their low 
expression in recombinant hosts and their inherent instability in surfactants. It was not until 
the year 2000 that the first high resolution GPCR structure was resolved by X-ray crystal-
lography, Rhodopsin in its inactive state [1]. The following 10 years witnessed the release 
of other inactive state crystal structures of class A GPCRs (e.g. the Adenosine A2A, and the 
β1 and β2 adrenergic receptors [2–4]), in addition to the release of the active state crystal 
structure of Rhodopsin in complex with a synthetic peptide resembling the C-terminus of the 
G-alpha subunit of transducing [5]. Available structures during that time served as templates 
for homology modeling for other GPCRs including the CB1 receptor. And parallel with bio-
physical studies, available crystal structures provided structural insights for their activation 
mechanism. A breakthrough in GPCR structural characterization has been achieved in the 
last 8 years with more than 200 structures for different GPCRs being deposited in the Protein 
Data Bank, including the CB1 inactive and active state crystal structures which have been 
resolved in 2016, and in 2017 respectively [6–8]. Before that, structural characterization of CB1 
orthosteric as well as allosteric binding domains have been extensively studied via mutations, 
site-directed labeling, mass spectrometry, SAR studies, and in-silico methods, and will be 
discussed in detail throughout this chapter.
2. Structural divergence of the cannabinoid receptors from class  
A GPCRs
The CB1 receptor is a class A (Rhodopsin-like) GPCR (Figure 1). Different phylogenetic stud-
ies and multidimensional scaling analysis of Class A GPCRs classify cannabinoid receptors 
(CB1/CB2) into one cluster along with the endothelial differentiation G-protein coupled recep-
tors (EDGRs) (including Sphingosine 1-phosphate receptors (S1P) and Lysophosphatidic acid 
receptors (LPA)) [9–12]. Receptors from those families, except for the LPA
4–6
, share common 
sequence divergence from other Class A GPCRs. Specifically, the absence of helix kinking 
proline residues in TMH2 and TMH5, and the absence of a disulfide bridge between the EC-2 
loop and C3.25 at the EC end of TMH3. Instead, they share an internal disulfide bridge in 
the EC-2 loop, a conserved PxxGW motif at the EC end of TMH4, in addition to a Y5.39 that 
forms an aromatic pi-pi stack with W4.64 in that motif resulting in a similar shape of the EC2 
loop as seen in the crystal structures for the CB1, S1P
1
, and LPA
1
 receptors [6, 7, 13, 14]. At the 
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binding site, they share a common basic residue (K/R 3.28) on TMH3 and an aromatic residue 
(F/Y 2.57) on TMH2. In addition, the S1P receptors are like CB1/CB2 in the presence of E1.49 at 
TMH1. E1.49 has been reported to be a key interaction site for pregnenolone (an endogenous 
negative allosteric modulator that protects the brain from cannabis intoxication) with CB1 
[15], while the LPA
1–3
 receptors share a W5.43 with CB1/CB2 that has been shown to affect 
antagonist binding to the cannabinoid receptors [16]. In addition, S1P
1
, and the cannabinoid 
receptors recognize lipid-derived ligands that have been shown to bind to the receptor by 
diffusing from bulk lipid towards the binding site via a transmembrane portal [6, 7, 14, 17, 18].
Figure 1. Helix net representation of the hCB1 receptor. The most highly conserved residue in each helix is shown in 
bold. Residues are numbered using the BW#: Ballesteros-Weinstein residue numbering system in GPCRs which uses 
the X.YY format; X denotes the transmembrane helix number and (YY) denotes residue position relative to the most 
conserved residue in the helix (X.50). Loop regions are numbered using absolute sequence numbers.
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3. CB1 receptor crystal structures
Two inactive state crystal structures for the hCB1 receptor have been resolved. The first struc-
ture (PDB ID: 5TGZ) was resolved at 2.8 Å; the receptor was truncated at both the N-terminus 
(1–98) and the C-terminus (415–472), with a flavodoxin protein fused into the IC3 loop (V306, 
P332), the receptor was crystalized in complex with a biaryl-pyrazole derivative (AM6358, 
Figure 2) and using thermo-stabilizing mutations (T3.46A, E5.37K, T5.47V, and R6.32E) [6]. 
The second structure was resolved at 2.6 Å (PDB ID: 5U09) in complex with an acyclic high 
affinity inverse agonist of the CB1 receptor, taranabant (Figure 2) [7]. In this structure, fewer 
amino acid residues were truncated from the N-terminus (1–76) and the C-terminus (422–472), 
and P. abysii glycogen synthase protein was fused into the IC3 loop (A301, D333) of a single 
point mutant (T3.46A) hCB1 receptor [7]. In both structures, resolved residues were from E100 
at the N-terminus to F412 at the C-terminus of the receptor.
Figure 2. Compounds discussed in this chapter.
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Agonist bound hCB1 crystal structures (PDB IDs: 5XRA, 5XR8) were resolved at 2.80 and 
2.95 Å resolution and in complex with the classical cannabinoids (AM11542, AM841) respec-
tively (Figure 2). The receptor was constructed in a similar way to the AM6358-bound crystal 
structure. Resolved residues included D104-S414 and F102-S414 in the 2.80 and 2.95 Å resolu-
tion structures respectively [8].
Inactive state CB1 structures show a transmembrane portal for antagonist entry between TMH1 
and TMH7 that is similar to the S1P1 structure. However, the membrane proximal region in the 
CB1 receptor forms a loop that extends towards the orthosteric binding site with two amino 
acid residues (F102, M103) invading unpredictably the binding site in the inactive state struc-
tures and forming Van der Waal (VDW) interactions with the antagonists (Figure 3) [6, 7].
Active state structures show characteristic conformational changes featuring class A GPCR 
activation including an outward movement and a counterclockwise rotation (EC view) of the 
IC end of TMH6, resulting in a break in the R3.50/D6.30 inactive state “ionic lock” [19, 20]. 
Unlike inactive state structures, a transmembrane portal is not present in active state structures 
due to the packing of the EC domain of TMH1 towards TMH7. In addition, the N-terminus 
resides at the top of the receptor with no invasion of the orthosteric binding site. On the other 
hand, the active state binding site displays a profound (53%) reduction in size that is resulting 
from an inward kink of the EC domain of TMH2 towards the orthosteric binding site, as well 
as, rotation of TMH3 towards TMH2 [8].
4. Mutation and labeling studies on CB1: consistency with CB1 
crystal structures
Multiple mutation studies on either mCB1 or hCB1 were aimed to study the receptor’s bind-
ing site and to identify key residues for CB1 receptor activation (Figure 4). While different 
ligands where used in functional and binding affinity assessment, WIN55212, SR141716A and 
CP55940, were used primarily, due to the availability of tritiated versions of these compounds. 
Figure 3. N-terminus residues F102 and M103 (green VdW) penetrate the binding crevice in the inactive state CB1 
structure (PDB ID: 5U09. This influences the positions of K3.28 (magenta tube), D2.63 and D184 (wheat tube) which form 
an interaction with each other.
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Figure 4. Mutations in or near the binding crevice of the CB1 receptor. The key represents changes in binding affinities 
of ligands to mutant CB1 receptor compared to WT. Residues are numbered using Ballesteros-Weinstein numbers. See 
Figure 1 for more details.
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Other ligands characterized include HU210, ∆9-THC, taranabant, and AM251. The discussion 
here will be focused on mutation and labeling studies near the orthosteric binding site and 
those affecting crystalized ligands or closely related structures such as SR141716A, HU201, or 
CP55940 (Figure 2).
4.1. K3.28 residue
One of the earliest mutational studies on the CB1 receptor targeted K3.28 [21, 22]. The lipophilic 
nature of CB1 ligands and the fact that the third TMH in CB1 has a V3.32 instead of an acidic 
residue at that position (as being conserved in aminergic receptors), directed the attention 
towards K3.28 to investigate its role in ligand binding.
Song and Bonner first reported that the binding of CP55940, HU210, and anandamide to a 
K3.28A mutant hCB1 expressed in HEK293 cells resulted in severe impairment, with more than 
100-fold decrease in their potencies in inhibiting cAMP accumulation. On the other hand, the 
binding and the potency of WIN55212 at the K3.28A mutant receptor were comparable to WT, 
suggesting that the receptor is still functioning [21]. Shortly afterwards, Kendall’s Lab dem-
onstrated retained binding affinity and potency for CP55940 in CHO cells expressing K3.28R 
hCB1 mutant, with no binding for up to 75 nM concentration in cells expressing K3.28Q or 
K3.28E mutants compared to cells expressing WT receptor (K
d
 = 7.7 ± 3.5 nM). In the same 
study, WIN55212 displayed comparable affinity for the three mutants with more than one order 
of magnitude decrease in potency in the K3.28E mutant, while its potency in K3.28Q mutant 
was not determined due to low receptor density [22]. A significant loss of CP55940’s potency 
in stimulating [35S]GTPγS binding in HEK293 cells expressing the K3.28A hCB1 mutant were 
also reported where the EC
50
 values for the WT and the mutant receptor were 1.3 and 225 nM 
respectively [23].
Results suggested that the loss of potencies of anandamide, and the classical and non-classical 
cannabinoids, but not WIN55212 at the K3.28A mutant is due to their low affinities to the 
receptor, and a basic residue at 3.28 is required for CP55940 binding. Based on mutation data, 
modeling studies suggested a hydrogen bond interaction between K3.28 and the amide oxygen 
of anandamide [16, 24], and with classical and non-classical cannabinoids [25–27]. While Shim 
argued later that K3.28 is important for stabilizing the binding site for the endocannabinoids 
and the classical and non-classical cannabinoids and not directly involved in their binding [28].
K3.28 mutations have also been demonstrated to affect affinities and deactivation profile 
of biaryl-pyrazole derivatives. The affinity of SR141716A to K3.28A hCB1 mutant has been 
reported to be 17-fold lower compared to the WT [29]. In addition, SR141716A was reported 
to act as neutral antagonist with loss of ability to turn off receptor’s basal activity in inhibiting 
Ca2+ currents in SCG neurons microinjected with K3.28A hCB1 mutant cDNA [30]. This data 
prompted a mutant cycle study using an SR141716A analog (VCHSR) to test the hypothesis 
that an interaction between the carboxamide oxygen in SR141716A and K3.28 is essential 
for its inverse agonist activity. The results supported the hypothesis by demonstrating that 
VCHSR acts as neutral antagonist with comparable affinities to both K3.28A and WT receptor 
[29]. A set of SR141716A analogues were also designed later that support the hypothesis [31]. 
A K3.28L mutation at hCB1 has been also reported to lower the binding affinity of AM251 by 
17-fold compared to the WT, while it had no effect on the affinity of the acyclic antagonist, 
taranabant, to the receptor [32]. The discriminatory effect of K3.28 mutants on different classes 
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of antagonists may suggest different binding interactions within the receptor’s binding site, 
especially that taranabant acts also as an inverse agonist [33].
CB1 crystal structures, on the other hand, do not support proposed hydrogen bonding of 
ligands to K3.28. In both inactive state and the active state structures of CB1, K3.28 orients its 
side chain towards the TMH2/3 interface forming salt bridges with D184 in the EC1 loop and 
D2.63 at the top of TMH2. The K3.28/D2.63 interaction is only noticeable in the inactive state 
crystal structures (Figure 3).
4.2. D2.63 mutations
As described above, this residue forms a salt bridge with K3.28 in the inactive state crystal 
structures (Figure 4). This K3.28/D2.63 salt bridge has been previously proposed to be essen-
tial for CB1 basal activity [34]. However, an earlier study on K3.28A mutant reported a compa-
rable basal activity to the WT receptor in inhibiting Ca2+ currents which does not support the 
role of K3.28/D2.63 salt bridge in controlling receptor’s basal activity [30]. Individual effects of 
D2.63 mutation on ligand binding and receptor activation have been also reported. In HEK293 
cells expressing a D2.63N hCB1 mutant, binding affinities for the classical cannabinoid 
(HU210), non-classical cannabinoid (CP55940), and the amino alkyl indole (WIN55212) were 
not significantly different from WT, while the affinity for SR141716A was 5-fold decreased 
compared to the WT. In addition, the potencies of CP55940 and HU210 in stimulating [35S]
GTPγS binding were significantly different from WT with about 12-fold increase in their 
EC
50
 values, while the basal activity of the D2.63N mutant was not different from WT [35]. 
In a different study, a double hCB1 mutant (L3.43A/D2.63A) was shown to lower the affinity 
of CP55940 to the receptor by 7-fold, while increasing the affinity of SR141716A by 3-fold. 
The L3.43A single mutant had an opposite effect by increasing the affinity of CP55940 to the 
receptor by 6-fold and lowering the affinity of SR141716A by 7-fold. Knowing that L3.43A 
mutation has been shown to increase the basal signaling of CB1 receptor in stimulating [35S]
GTPγS binding, combining D2.63A with L3.43A mutation lowered the basal signaling below 
CB1 WT levels. Results suggest that D2.63 may be involved in receptor activation and that 
mutation into alanine stabilizes the inactive state of the receptor [34, 36]. A modeling and 
mutation study suggested that an ionic interaction between D2.63 and K373 in the EC-3 loop 
is important for receptor activation. In the study, a reciprocal mutant D2.63K/K373D resulted 
in similar potencies for CP55940 and WIN55212 in stimulation for [35S]GTPγS compared to 
the WT receptor, while their potencies were more than 5-fold lower in the single and double 
alanine mutants [37]. Such an interaction is not present in the crystal structures.
4.3. Mutation studies on the CB1 N-terminus
The CB1 receptor is unique in having a relatively long (114 amino-acid residues) N-terminus 
compared to other class A GPCRs. Analysis of the amino acid sequence of the membrane prox-
imal region (MPR) of the amino terminus reveals a remarkably high degree of conservation in 
that region (Figure 5).
Early studies on the N-terminus reported no effect on prolylglycine insertion in the N-terminus 
(at A73, L86, and E100) of hCB1 receptor expressed in HEK 293T cells on agonist (CP55940) and 
antagonist (SR141716A) binding. In addition, S1.30A and Q1.31A mutants at the N-terminal 
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Figure 5. Sequence alignment of the CB1 N-terminus of 11 different species downloaded from the UniProt online 
database (www.uniprot.org).
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end of TMH1 did not affect the binding affinity for SR141716A, while they reduced the bind-
ing affinity of CP55940 by 5- and 10-fold respectively [38].
In addition, CP55940 binding to truncated receptor at the N-terminal region (Δ64, Δ80, Δ89, 
Δ103 shCB1) was comparable to the WT receptor [39, 40]. On the other hand, the binding 
affinity of SR141716A to the Δ103 synthetic hCB1 (shCB1) truncation mutant was higher com-
pared to the WT with retained ability to inhibit basal signaling of the truncated mutant [39]. 
As described earlier, in the (inactive state CB1 X-ray crystal structures, two amino acid resi-
dues from the N-terminus occupy the receptor’s orthosteric binding site, forming strong VDW 
interactions with the antagonists, those are F102, M103. Affinity data of SR141716A to the Δ103 
shCB1 truncation mutant is inconsistent with the inactive state crystal structures.
Reduction of the proposed disulfide bridge at the N-terminus C98/C107 reduces CP55940 
potency in [35S]GTPγS binding assay [39]. However, a previous study reported that a double 
mutant of the two cysteine residues into serine subtly affected CP55940 binding, but did not 
affect SR141716A binding [41]. It is worth-mentioning that the C98/C107 residues are con-
served among all 11-CB1 species available from UniProt. This sulfide bridge is not apparent in 
crystal structures.
Interestingly, a recent mutational, and modeling study from the Kunos lab identified an 
N-terminal residue (M106 in rodent CB1 compared to I105 in hCB1) as the determinant of 
the species differential affinity of {5-(4-chlorophenyl)-N-{(1R,2R)-2-hydroxycyclohexyl}-6-(2-
methoxyethoxy)-3-pyridinecarboxamide} (14 h) at the CB1 receptor [42]. The compound, has 
been described previously as a peripherally selective, high affinity CB1 receptor antagonist 
[43]. However, this compound has been shown to have higher affinity for the hCB1 receptor 
compared to mouse and rat CB1 receptor [42]. This residue faces the ligand binding site in 
crystal structures, but with a changed position in the different structures.
4.4. EC1 loop
Mutations of the EC1 loop negatively impacted CP55940 but not SR141716A binding, the K
i
 value 
of CP55940 was 26-fold higher in D184A hCB1 mutant compared to the WT receptor expressed in 
HEK293 cells. Here, the K
i
 was determined by competition binding against [3H]SR141716A [38]. 
This aspartate residue forms an ionic interaction with K3.28 in both the active and inactive state 
CB1 crystal structures (Figure 3) [6–8]. H181A, R182A, and K183A have also lowered CP55940 
affinity by 3–4-fold compared with the WT [38]. None of the EC1 loop residues forms direct 
contact with crystallized ligands.
4.5. Aromatic residues lining the orthosteric binding site
The orthosteric binding site of CB1 is lined with multiple aromatic residues located on TMH2/ 
3/5/6/7, as well as, F286 in the EC2 loop.
4.5.1. F2.57, F2.61, and F2.64
F2.57 is two turns extracellular to the conserved D2.50, facing the orthosteric binding site. 
In the inactive state CB1 crystal structures, this residue has been shown to form an aromatic 
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π-π stack with the 2,4-dichlorophenyl ring in AM6538 [6], and with the cyanophenyl ring in 
taranabant [7]. Mutation data show a reduced affinity for taranabant and AM251 (a diarylpyr-
azole antagonist) by 30- and 97-fold respectively in F2.57L hCB1 mutant [32]. In addition, both 
SR141716A and AM6538 failed to antagonize 100 nM CP55940-induced inhibition of cAMP 
in F2.57A hCB1 mutant while preserving their abilities in F2.57W hCB1 mutant [6]. Results 
indicate a major role for this residue in antagonist binding via aromatic interactions and in 
shaping the antagonist binding site. On the other hand, while this residue shows a major 
contact with the agonists (A-ring, Figure 2) in the AM11542 and the AM841 bound crystal 
structures, [8] CP55940 displayed similar potency for inhibition of cAMP in both F2.57A, and 
F2.57W mutants compared to WT [8].
Mutations on F2.61 revealed effects on antagonist and agonist binding and potencies. In the 
inactive state CB1 structures, this residue is rotated towards TMH1 and its side chain is at the 
TMH1/TMH2 interface, yet it forms moderate VDW interactions with the piperidine and with 
the trifluoro-methyl pyridine in AM6538 and taranabant respectively [6, 7]. While in the active 
state structures, this residue faces the binding site and forms strong VDW interactions with the 
agonists (AM11542 and AM841) B-ring (Figure 2) [8]. SR141716A displayed only 5-fold higher 
K
d
 value in F2.61A hCB1 mutant transiently expressed in HEK293 cells [44], but both SR141716A 
and AM6538 failed to antagonize 100 nM CP55940-induced inhibition of cAMP in F2.61A mutant 
while preserving their potencies in F2.61W mutant (mutations were on hCB1, and functional 
assays were done in stably transfected CHO cells) [6]. Also, CP55940 displayed similar potency 
in both F2.61A and F2.61W in inhibition of cAMP compared to the hCB1 WT stably transfected 
in CHO cells, [8] while the binding affinities for CP55940, HU210, and ∆9-THC determined 
against [3H]SR141716A were severely affected by F2.61A mutation transiently transfected in 
HEK293 cells [45]. In the same study, the potency of HU210 in inducing [35S]GTPγS binding has 
been reported to be 30-fold less in F2.61A hCB1 mutant compared to the WT [45].
The F2.64A mutation has also been shown to be detrimental for agonists (HU210, CP55940, 
and ∆9-THC) binding [45]. CP55940, AM841, and AM11542 displayed about an order of mag-
nitude lower potency in inhibition of forskolin-stimulated cAMP in CHO cells expressing the 
mutant receptor [8]. In crystal structures, this residue forms major contacts with the agonists’ 
(C-ring, Figure 2) [8], and does not display any contact with the antagonists due to the pres-
ence of the N-terminus [6, 7], and no mutation data are available to characterize antagonists 
binding or potency in this mutant.
4.5.2. F3.25
Different studies determined binding affinity of CP55940 to F3.25A mutant; in one study, the 
binding affinity of CP55940 determined by saturation binding against [3H]SR141716A was 
60-fold lower in F3.25A hCB1 stably transfected in CHO-K1 cells compared to WT [38]. In 
other studies, CP55940 affinity was not affected in F3.25A mCB1 mutant receptor stably trans-
fected into HEK293 cells, affinity was determined using [3H]CP55940 [16, 46]. The discrepancy 
in binding affinities here could be due to species differences. F3.25A did not affect SR141616A 
binding in those studies [16, 38, 46]. Basal [35S]GTPγS binding was also determined for the 
F3.25A mCB1 mutant stably transfected in HEK293 cells and was not significant from WT, 
while the WIN55212-2 induced [35S]GTPγS binding was lower in the mutant with EC
50
 value 
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being 6-fold higher compared to the WT. In crystal structures, this residue shows moderate 
VDW interactions with the crystallized agonists (C-ring, Figure 2) [8], and no direct interac-
tions with the antagonists [6, 7].
4.5.3. Y5.39, W5.43
Y5.39 is a conserved residue in many class A GPCRs. In the active state crystal structures, Y5.39 
interacts with the agonists and forms a hydrogen bond interaction with the isothiocyanate 
moiety in AM841. Mutation data published along with the crystal structures show that muta-
tion of this residue in hCB1 into phenylalanine or alanine results in significant reduction in 
the potencies of CP55940, AM841, and AM11542 in the inhibition of forskolin-induced cAMP, 
with pEC
50
 values for CP55940 being 8.3 ± 0.15 for the WT and 6.7 ± 0.13 and 5.4 ± 0.95 for the 
Y5.39F and Y5.39A mutants respectively [8]. Efficacy data for CP55940 are consistent with 
previous report from Abood’s Lab [47]. In this report, WIN55212-2 has been shown to retain its 
WT potency in the Y5.39F mutant. In addition, the Y5.39F hCB1 mutant generally retained WT 
binding affinities for CP55940, ∆9-THC, WIN55212-2, and SR141716A and resulted in 17-fold 
lower K
i
 value for anandamide. On the other hand, Y5.39I hCB1 mutant resulted in loss of 
ligand binding. Authors concluded that aromaticity is required at this position [47]. Results 
from Abood’s lab suggest that aromaticity is required for ligand binding generally, while the 
phenolic ring is required for signal transduction for classical and non-classical cannabinoids.
The W5.43A mutation in mCB1 was detrimental for the binding of SR141716A [16, 46], this 
mutation also negatively affected the binding affinity of AM251 to the mutant hCB1 with 54-fold 
lower affinity, while it resulted in only 7-fold lower affinity for taranabant [32]. This mutant 
resulted in 16-fold reduction in affinity of WIN55212-2, but did not affect either CP55940 or 
anandamide binding [16, 46]. The potency of CP55940 in stimulation of [35S]GTPγS, however, 
was 66-fold lower in the mutant receptor compared to the WT, while the basal [35S]GTPγS 
binding for the W5.43A mutant being comparable to WT [46]. In active state crystal structures, 
this residue forms strong VDW interaction with AM841 and AM11542 aliphatic tails. In inac-
tive state structures, the residue forms moderate VDW interactions with the 4-chlorophenyl 
ring in taranabant and the aliphatic chain-substituted phenyl ring in AM6538, an interaction 
that is inconsistent with the mutation data which suggests that W5.43 stabilizes the binding 
site of the antagonists, rather than being a strong interaction site with the antagonists.
4.5.4. W6.48, F3.36: the rotamer toggle switch
W6.48 belongs to the conserved CWXP hinge motif in TMH6. A W6.48 χ1 rotameric state 
change from g+ to trans has been proposed to be the binding pocket trigger for the hinge 
motion of TMH6 that occurs during receptor activation. Here the IC end of TMH6 moves away 
from the TMH bundle, providing an opening into which the alpha-5 helix of the G-protein can 
insert [48–52]. This rotameric change is manifest for class A GPCRs in Molecular Dynamics 
(MD) simulations [18, 53–55], even though available active state crystal structures of class A 
GPCRs do not show evidence for this rotameric change. The W6.48A mCB1 mutation resulted 
in a 7-fold increase in binding affinity (K
i
) of SR141716A compared to the WT receptor, while 
it had no effect on the dissociation constant of CP55940 [16, 46]. In the CB1 crystal structures, 
only antagonists show mild VDW interaction with W6.48.
Recent Advances in Cannabinoid Research44
Computational modeling and mutation studies targeting F3.36 in CB1 receptor suggested that 
the F3.36/W6.48 interaction represents a toggle switch that stabilizes the inactive state of the 
receptor [46, 56]. Consistent with the inactive and active state CB1 crystal structures, the mod-
eling study suggested that F3.36/W6.48 contact is broken during activation with a rotameric 
change of the χ1 dihedral of F3.36 from trans in the inactive state to g+ upon activation. The 
F3.36A CB1 mutation resulted in increased basal signaling of the receptor and did not affect 
the CP55940 dissociation constant, but reduced the binding affinity of SR141716A [16, 46, 57, 
58]. An F3.36L mutation generally restored the binding affinity of SR141716A to the receptor 
[57]. In a different study, the F3.36L mutation resulted in a 7- and 9-fold lower binding affini-
ties for taranabant and AM251 respectively [32]. In the CB1 crystal structures, only agonists 
show mild VDW interaction with F3.36 via their dimethyl substituent. Thus, the reduction 
in the binding affinity of SR141716A to the F3.36A mutant could be a result of shifting the 
equilibrium towards active state.
While the rotameric change of F3.36 only and not W6.48 is evident in the CB1 crystal struc-
tures, it is essential to notice that this change requires a synchronized rotameric change in the 
χ1, as well as, the χ2 dihedrals of W6.48. Thus, it could be proposed that a transient rotameric 
change in χ1 dihedral of W6.48 from g+ to trans or vice-versa is required to permit conforma-
tional changes in F3.36. In addition, the major rotameric change in F3.36 is associated with a 
rotational movement of TMH3 towards TMH2. Agonists appear to stabilize this conforma-
tional change in TMH3 by blocking F3.36 in g+, thus stabilizing the active state of the receptor. 
While in the inactive state structures, it could be noticed that the antagonists seem to prohibit 
the rotameric change of W6.48 into trans, thus acting as inverse agonists at the CB1 receptor.
4.5.5. F7.35
This residue has been shown to mildly affect SR141716A binding with ~4-fold increase in K
d
 in 
F7.35A hCB1 mutant [44]. Potencies of SR141716A and AM6538 in inhibiting 100 nM CP55940 
activity were also retained in F7.35A and F7.35W hCB1 mutations [6]. However, the potency 
of CP55940, AM841, and AM11542 in inhibition of forskolin-induced cAMP has been shown 
to be around one order of magnitude affected by F7.35W mutation which might be due to 
steric hindrance, while their potencies were majorly affected by a 7.35A mutation [6, 8]. This 
residue shows moderate VDW interactions with the gem dimethyl group at C1’ of agonists 
and very mild VDW interactions with the antagonists in the active and inactive state crystal 
structures respectively.
4.6. EC2 loop residues
The CB1 EC2 loop lines the binding site with five amino acid residues residing on top of 
the ligand binding site; 267-IFPHI-271. Mutations at the EC2 loop have been shown to affect 
CP55940 binding generally and have no effect on SR141716A binding. Replacement of the 
entire hCB1 EC2 loop (254-GWNCEKLQSVCSDIFPHIDETYL-276) by the hCB2 EC2 loop 
(GWTCCPRP - - CSELFPLIPNDYL) did not affect SR141716A binding but resulted in a com-
plete loss of CP55940 binding, while replacing EKLQSV in CB1 by CPRP (CB2/EC2) resulted 
in receptor sequestration [41]. In addition, the C257/C264 internal disulfide bridge has been 
determined to be required for membrane expression [41, 59]. Single point alanine mutations 
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were investigated for the majority of the EC2 loop. Among the residues that face the binding 
site, F268A/N hCB1 mutation impaired receptor membrane expression. F268Y hCB1 mutation 
had no effect on ligand binding, while F268W mutation drastically affected CP55940 binding 
with no effect on SR141716A binding. In addition, P267A, H270A, and I271A mutants showed 
no effect on SR141716A binding while drastically affecting CP55940 binding [60]. In crystal 
structures, F268 forms strong VDW interaction with both agonists and antagonists in addi-
tion to an aromatic stacking with the agonists. P267 and I271 form week VDW interaction 
with agonists while the H270 side chain points towards TMH3 and is packed against F3.25. 
In addition, due to closer packing of the EC end of TMH5/6 towards the ligand binding site 
in the active state compared to the inactive state, and the fact that agonists are cupping F268 
compared to the antagonists, it could be interpreted that F268W mutation data regarding the 
binding of agonists versus the antagonists could be consistent with crystal structures.
4.7. Cysteine residues in the EC domain of CB1; labeling and mutation studies
Among the 13 cysteine residues in the CB1 receptor, C6.47, C7.38, and C7.42 reside in the EC 
transmembrane domain and are not engaged in a disulfide bond. C6.47 is only available in the 
binding pocket in the activated state of Class A GPCRs. Consistent with this, the earliest CB1 
cysteine reactivity study using the isothiocyanate derivatized agonist, AM841, showed that 
AM841 labels C6.47 [61]. A subsequent study showed that AM841 also labels C6.47 in CB2 [62]. 
The isothiocyanate derivatized anandamide analog, AM3677, was also found to label C6.47 
[63]. This has led to the hypothesis that cannabinoid agonists enter CB1 via a portal between 
TMH6 and TMH7 at the level of C6.47. The active state crystal structure, is not consistent with 
cysteine crosslinking studies of AM841, since the AM841 alkyl tail points towards Y5.39 in the 
crystal structure.
In another cysteine reactivity study, C7.42, was found reactive, suggesting that it faces the 
binding pocket. Mutation of C7.42 to a larger amino acid resulted in loss of SR141716A bind-
ing, but not CP55940 binding. In all reported crystal structures, C7.42 faces into the binding 
pocket. Further, if C7.42 is mutated to M in the active state structure, it does not affect the 
agonist binding pocket. However, a methionine residue at that position in the inactive state 
structures clashes severely with the antagonists and surrounding residues, such clashes are 
not relieved by rotameric changes for nearby residues.
4.8. Serine residues in CB1
Mutation of S7.39 in hCB1 to alanine in was generally detrimental for CP55940, HU201 and 
AM4056 binding to the CB1 receptor, while it had no effect on the binding affinities for 
SR141716A, AM251, as well as, WIN55212 [32, 57, 64]. On the other hand, it resulted in a pro-
found reduction in the binding affinity of taranabant to the receptor [32]. In the inactive state 
crystal structure in complex with taranabant, as well as, the active state crystal structure, there is 
a hydrogen bond interaction between S7.39 and the ligand. The residue adopts a g− χ1 dihedral 
that allows this interaction. In the AM6358/inactive state crystal structure, this residue adopts a 
g+ χ1 dihedral. In this structure, the ligand is incapable of forming a hydrogen bond interaction 
with S7.39, since such an interaction requires a high energy conformation of the antagonist.
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Mutation data show that the S2.60A mutation in hCB1 has no effect on the binding affinities 
of both CP55940 and SR141716A [64]. S2.60 does not seem to be involved in any interactions 
with ligands in the crystal structures. This is due to the rotation of TMH2 towards TMH3 
caused by the G2.53/S2.54 motif in TMH2 allowing a wider turn in that region.
4.9. L3.29A, M6.55A, and T3.33A mutations
L3.29 faces the ligand binding site and has been shown to interact with both agonists and 
antagonists. Such interactions are stronger in the active state due to the rotation of TMH3 
towards TMH2, allowing L3.29 to be more oriented towards the binding site. The L3.29A muta-
tion in hCB1 has been shown to mildly affect the binding affinity of SR141716A to the receptor, 
while having a profound effect on the binding of CP55940, HU210 and ∆9-THC. The L3.29A 
mutations resulted in reduced efficacy of both HU210 in stimulation of [35S]GTPγS binding and 
in the efficacy of CP55940 in the inhibition of forskolin-induced cAMP accumulation [8, 44, 45].
Both T3.33A and M6.55A mutations did not have any effect on the binding affinity of 
SR141716A which is consistent with the inactive state crystal structures [44]. M6.55A muta-
tion in hCB1 resulted in a 15- and 4-fold reduction in the affinity of HU210 and CP55940 
respectively while it did not affect the affinity of ∆9-THC [45]. This residue shows moderate 
VDW interactions with the agonists in the crystal structures.
5. NMR and circular dichroism (CD) studies on the C-terminus
Both NMR and CD studies have been performed on the C-terminus of CB1 employing pep-
tide segments that correspond to that receptor region. Results show a helical segment resem-
bling helix 8 that is parallel to the plane of the membrane [65–67]. Ahn et al., reported two 
amphipathic α-helical domains; S410-F412 that corresponds to helix 8, and a second helical 
segment (A440-M461) that is also parallel to the membrane, (Figure 1) [65].
6. Crystal contacts
In the inactive and active state CB1 crystal structures, crystal packing impinges on the ligand 
binding site (Figure 6). In the first published CB1 inactive state structure [6], receptor bundles 
are crystallized top-to-top, forcing the N-terminus to invade the binding pocket and flatten-
ing the EC loops. In the second inactive state CB1 structure [7], adjacent bundles impinge on 
receptor EC loops and N-terminus around the “rim” of the receptor’s EC domain (Figure 6). 
The effect on CB1 structure is similar to that discussed above for the first inactive crystal 
structure. Crystal packing in the active state structure [8] also causes an impact on the CB1 
binding pocket. Packing causes TMH2 to hinge at G2.53/S2.54 (S2.54 has a χ1 = g−) and invade 
the binding pocket. Packing also impacts the N-terminus, TMH1 above N1.50, the EC top of 
TMH3, the EC-2 loop and the EC end of TMH4.
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Such packing issues can promote non-genuine conformations in the structure that is promoted 
by the crystalline low energy state. A recently published crystal structure of the μ-opioid 
receptor (MOR) has revealed a histidine H54 residue in the N-terminus of the receptor that 
Figure 6. Unit cell TM region and extracellular loop crystal contacts for hCB1 receptor crystal structures. CB1 ribbon 
colors: TMH1 (red), TMH2 (orange), TMH3 (yellow), TMH4 (pale green), TMH5 (green), TMH6 (cyan), TMH7 (blue), 
crystal mate ribbons (white). Top panel: inactive state structure (PDB ID: 5TGZ) [6]. Middle panel: inactive state structure 
(PDB ID: 5U09) [7]. Bottom panel: active state structure (PDB ID: 5XRA) [8]. Amino acid residues for crystal mates are 
colored cyan, while inactive and active state structures are shown in orange and green respectively.
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is positioned 2.6 Å from the secondary amine of the bound agonist. Mutation of this residue 
into alanine did not affect the affinity of the ligand to the receptor, suggesting that the result-
ing conformation of the N-terminus in MOR structure is a result of crystallization and not 
relevant in the real state [68].
7. Conclusions
Because X-ray crystal structures are used frequently for drug design projects, it is critical to 
identify any issues with these structures, such as crystal packing effects and to evaluate how 
consistent these structures are with the body of structural information in the literature for a 
given receptor, such as mutation, cross-linking and NMR studies. Results presented in this 
chapter show that crystal packing issues impact both of the CB1 inactive state crystal structures 
and the activated state CB1 crystal structures. Impacts include N-terminus insertions deep into 
the binding pocket seen in the CB1 inactive state structures, as well as, TMH1 and TMH2 bend-
ing into the binding pocket seen in the activated state structures. Not surprisingly, we find 
here that the CB1 structures have important inconsistencies with mutation data, particularly in 
their TMH1-2-3 regions. In addition, the CB1 crystal structures do not capture the movement 
of W6.48 during receptor activation, or the existence of a ligand portal in the activated state, 
however, X-ray structures by their very nature will not capture all transient changes. In conclu-
sion, then, the CB1 crystal structures are an important contribution to the drug design field, 
but revisions are advisable before these structures are used for structure-based drug discovery.
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